Comparing Upadacitinib for Psoriatic and Rheumatoid Arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests whether the medication upadacitinib (Rinvoq) works similarly for psoriatic arthritis and rheumatoid arthritis. Participants will have ultrasound imaging to track joint inflammation while taking upadacitinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriatic arthritis (with active joint, tendon, or spine symptoms) OR rheumatoid arthritis (with active joint inflammation).
- You are at least 18 years old and a candidate for upadacitinib (Rinvoq) based on your doctor's evaluation.
- You do not have active infections, certain cancers, severe liver disease, or high risk for blood clots/heart problems.
- You are not pregnant or breastfeeding, and you do not have HIV or hepatitis B or C.
- You do not have fibromyalgia (as formally diagnosed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two newer oral medications—tofacitinib and upadacitinib—to see which works better and is safer when added to methotrexate for rheumatoid arthritis. Both medicines help calm the immune system's attack on joints.
This study tests an oral drug called AP1189 for people just diagnosed with active rheumatoid arthritis who haven't yet taken standard arthritis medicines. You may be able to take part if your disease is very active and you're ready to try a new treatment option.
This trial tests a new drug called A-319 for people with active rheumatoid arthritis (RA) that hasn't improved enough after trying other treatments. The goal is to see if A-319 can reduce joint pain, swelling, and inflammation.
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
This study looks at how well upadacitinib treats enthesitis (pain where tendons or ligaments attach to bone) in people with psoriatic arthritis. Researchers will use ultrasound to measure improvement. The trial is for adults who have already tried at least one biologic drug, including an anti-TNF, without success.
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.